This has already elicited interest from pharmaceutical companies."
The opportunity from an investment point of view is to monitor the developments and to see who gets the license to market the drugs developed as a therapeutic agent for preventing and treating autoimmune diseases such as type 1 diabetes.
............................
No comments:
Post a Comment